IPO - Profile

Pharvaris B.V.

Health Care > Major Pharmaceuticals



We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, PHA121, is a novel, small-molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. Bradykinin-B2-receptor inhibition is a clinically validated mechanism for the treatment of HAE, as demonstrated by icatibant, which is a bradykinin B2-receptor antagonist approved in Europe in 2008 and in the United States in 2011 (as FIRAZYR). We designed PHA121 to improve More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$20.00 8,300,000 Positive High 45.95%

Offering Team

  • Legal counsel
  • Kirkland & Ellis LLP
  • Auditors
  • PricewaterhouseCoopers LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 04 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $20.00
Offer Size 8M

Market Sentiments

Stock Price